4-甲氧基-2-甲基-3-氧丁酸乙酯 | 14966-69-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: 4-甲氧基-2-甲基-3-氧丁酸乙酯
• 英文名称: 4-Methoxy-2-methylacetessigsaeure-ethylester
• 英文别名: 2-methyl-3-keto-4-methoxybutyric acid ethyl ester；ethyl 2-methyl-3-oxo-4-methoxybutyrate；Ethyl 4-methoxy-2-methyl-3-oxobutanoate
• CAS: 14966-69-9
• 化学式: C₈H₁₄O₄
• mdl: MFCD07779204
• 分子量: 174.197
• InChiKey: ODDDUGHVGAOYKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  4-甲氧基-2-甲基-3-氧丁酸乙酯 以 甲醇 为溶剂， 生成 3-[(2,4-Dinitro-phenyl)-hydrazono]-4-methoxy-2-methyl-butyric acid methyl ester
  参考文献：
  名称：

  Failure to verify a reported synthesis of the aconitine skeleton

  摘要：

  DOI：

  10.1016/s0040-4039(00)87303-7
• 作为产物：
  描述：

  甲氧基乙酸甲酯 、 2-溴丙酸乙酯 在 锌 作用下， 以 苯 为溶剂， 生成 4-甲氧基-2-甲基-3-氧丁酸乙酯
  参考文献：
  名称：

  Failure to verify a reported synthesis of the aconitine skeleton

  摘要：

  DOI：

  10.1016/s0040-4039(00)87303-7

文献信息

• Pyrimidine derivatives and processes for the preparation thereof
  申请人：Yuhan Corporation

  公开号：US06352993B1

  公开（公告）日：2002-03-05

  The present invention relates to novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof which possess an excellent anti-secretory activity, pharmaceutical compositions containing the same as an active ingredient, their novel intermediates, and processes for the preparation thereof wherein: when A is piperidin-1-yl or —NH—B, wherein B is C3-C4 alkyl, C3-C4 alkenyl, C3-C7 cycloalkyl, C1-C3 alkoxyethyl, phenylethl which may be substituted or unsubstituted, 3-trifluoromethylphenylmethyl, 1-naphthylmethyl, 4-methylthiazol-2-yl or 4-phenylthiazol-2-yl, R1 is hydrogen or methyl; and R2, R3, R4 and R5 are hydrogen; or when A is a group of formula (II); when R1 is hydroxymethyl or C1-C3 alkoxymethyl, R2, R3, R4, R5 and R6 are hydrogen; and R7 is hydrogen or halogen; or when R1 is hydrogen or methyl, R7 is hydrogen or halogen; and one or two of R2, R3, R4, R5 and R6 is hydroxy, methoxy, or a group of formula (III) wherein Z is C1-C4 alkyl, substituted or unsubstituted C1-C4 alkenyl, cyloalkyl, benzyloxyalkyl, alkoxycarbonylalkyl, morpholinomethyl, piperidinomethyl, 4-substituted-piperazinomethyl, substituted or unsubstituted phenyl, naphthyl, substituted or unsubstituted benzyl, thiophen-2-yl-methyl, 1-substituted-pyrrolidin-2-yl or —CHR8NHR9, wherein R8 is hydrogen, methyl, isopropyl, benzyl, benzyloxymethyl, methylthioethyl, benzyloxycarbonylmethyl, carbamolymethyl, carbamoylethyl, or 1-benzylimidazol-4-ylmethyl and R9 is hydrogen or t-butoxycarbonyl; and the others are hydrogen or methyl.

  本发明涉及具有优异抗分泌活性的新型嘧啶衍生物的化学式(I)或其药学上可接受的盐，以及含有其作为活性成分的药物组合物，其新型中间体，以及其制备方法，其中：当A为哌啶-1-基或-NH-B时，其中B为C3-C4烷基，C3-C4烯基，C3-C7环烷基，C1-C3烷氧乙基，苯乙基，可以是取代或未取代的，3-三氟甲基苯甲基，1-萘甲基，4-甲基噻唑-2-基或4-苯基噻唑-2-基，R1为氢或甲基；而R2、R3、R4和R5为氢；或当A为化学式(II)的基团时；当R1为羟甲基或C1-C3烷氧甲基，R2、R3、R4、R5和R6为氢；而R7为氢或卤素；或当R1为氢或甲基，R7为氢或卤素；且R2、R3、R4、R5和R6中的一个或两个为羟基，甲氧基，或化学式(III)的基团，其中Z为C1-C4烷基，取代或未取代的C1-C4烯基，环烷基，苄氧基烷基，烷氧羰基烷基，吗啉甲基，哌啶甲基，4-取代哌嗪甲基，取代或未取代的苯基，萘基，取代或未取代的苄基，噻吩-2-基-甲基，1-取代吡咯啉-2-基或-NHR9，其中R8为氢，甲基，异丙基，苄基，苄氧甲基，甲硫乙基，苄氧羰基甲基，氨基甲基，氨基乙基，或1-苄基咪唑-4-基甲基，而R9为氢或叔丁氧羰基；其他为氢或甲基。
• Pyrimidylalkylthio benzimidale compounds, pharmaceutical compositions
  申请人：Smith Kline & French Laboratories Limited

  公开号：US04777172A1

  公开（公告）日：1988-10-11

  This invention relates to 2- and 4-pyrimidinylmethylsulphinyl(and thio)benzimidazoles in which the pyrimidyl group is substituted by an optionally substituted amino group. These compounds inhibit exogenously and endogenously stimulated gastric acid secretion.

  本发明涉及2-和4-嘧啶甲基磺酰基（和硫）苯并咪唑，其中嘧啶基被一个可选择取代的氨基基团取代。这些化合物可以抑制外源性和内源性刺激的胃酸分泌。
• Pyrimidylalkylthio benzimidazole compounds, pharmaceutical compositions
  申请人：Smith Kline & French Laboratories

  公开号：US04820708A1

  公开（公告）日：1989-04-11

  This invention relates to 2- and 4-pyrimidinylmethylsulphinyl(and thio)benzimidazoles in which the pyrimidyl group is substituted by an optionally substituted amino group. These compounds inhibit exogenously and endogenously stimulated gastric acid secretion.

  该发明涉及2-和4-嘧啶基甲基亚砜基（和硫）苯并咪唑，其中嘧啶基团被一个可选择性取代的氨基团取代。这些化合物能够抑制外源性和内源性刺激的胃酸分泌。
• MAPK/ERK KINASE INHIBITORS
  申请人：Dong Qing

  公开号：US20080255160A1

  公开（公告）日：2008-10-16

  Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  提供以下公式化合物用于与MEK一起使用：其中变量的定义如下。还提供了包含这些化合物的药物组合物、试剂盒和制造物品；用于制备这些化合物的方法和中间体；以及使用这些化合物的方法。
• Heterocyclic compounds
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0198583A1

  公开（公告）日：1986-10-22

  Compounds of structure (I) in which, R1 to R4 are the same or different and are each hydrogen, C1-6alkyl, halogen, trifluoromethyl, C1-6alkoxy, C1-6alkanoyl, C 1-6alkoxycarbonyl, RCF20, an ethoxy group substituted by 3 to 5 fluorine atoms, or R2 and R3 together form a group -O(CR2)m O-where m is 1 or 2, and each group R is hydrogen or fluorine; n is 0 or 1; R5 and R6 are the same or different and are each hydrogen, C 1-6alkyl or C3-6cycloalkyl, or R5 and R6 together with the nitrogen atom to which they are attached form an azetidino, pyrrolidino, piperidino, piperazino, N-C1- 4alkylpiperazino or morpholino group; and one of X and Y is a nitrogen atom, and the other is a group CR7 where R7 is hydrogen, C1-6alkyl or NH2; processes for their preparation; intermediates used in their preparation; compositions containing them and their use in therapy in the inhibition of gastric acid.

  结构(I)的化合物 其中，R1 至 R4 相同或不同，各自为氢、C1-6烷基、卤素、三氟甲基、C1-6烷氧基、C1-6烷酰基、C 1-6 烷氧基羰基、RCF20、被 3 至 5 个氟原子取代的乙氧基，或 R2 和 R3 共同形成一个基团-O(CR2)m O-其中 m 为 1 或 2，每个基团 R 为氢或氟；n 为 0 或 1；R5 和 R6 相同或不同，各自为氢、C 1-6 烷基或 C3-6 环烷基，或 R5 和 R6 与它们所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、N-C1- 4 烷基哌嗪基或吗啉基；X和Y中的一个是氮原子，另一个是基团CR7，其中R7是氢、C1-6烷基或NH2；它们的制备工艺；制备过程中使用的中间体；含有它们的组合物以及它们在抑制胃酸治疗中的用途。